Leitlinie erklärt

• Literatur

• 1 Kanis JA. et al. A meta‐analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19 (06) 893-899.
• 2 Yu SF. et al. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey. Med (Baltimore). 2017 Feb ; 96(5):
• 3 Ton FN, Gunawardene SC, Lee H. et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005; 20 : 464-470.
• 4 Smolen JS. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheumatic Dis 2017; 76 (06) : 960-977.
• 5 Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: Who to treat with what agent? Nat Rev Rheumatol 2015; 11: 98-109.
• 6 Van Staa TP. et al. Use of oral corticosteroids and risk of fractures June, 2000. J Bone Miner Res 2005; 20: 1487-1494. discussion 1486